ALX Oncology Stock (NASDAQ:ALXO)
Previous Close
$1.23
52W Range
$1.21 - $17.82
50D Avg
$1.67
200D Avg
$7.99
Market Cap
$63.82M
Avg Vol (3M)
$684.68K
Beta
1.04
Div Yield
-
ALXO Company Profile
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
ALXO Performance
Peer Comparison
Ticker | Company |
---|---|
CGEM | Cullinan Oncology, Inc. |
DYN | Dyne Therapeutics, Inc. |
RVMD | Revolution Medicines, Inc. Warrant |
EYPT | EyePoint Pharmaceuticals, Inc. |
BCAB | BioAtla, Inc. |
MLYS | Mineralys Therapeutics, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
BMEA | Biomea Fusion, Inc. |
STOK | Stoke Therapeutics, Inc. |
IPSC | Century Therapeutics, Inc. |
AVTE | Aerovate Therapeutics, Inc. |
IMTX | Immatics N.V. |
BDTX | Black Diamond Therapeutics, Inc. |
BCEL | Atreca, Inc. |
VIRX | Viracta Therapeutics, Inc. |
PASG | Passage Bio, Inc. |
CABA | Cabaletta Bio, Inc. |
CRNX | Crinetics Pharmaceuticals, Inc. |
CCCC | C4 Therapeutics, Inc. |